Skip to Main Content
  • About
    • Staff
    • Board of Directors
    • Member Directory
  • Membership
    • Membership Benefits
    • Membership FAQ
    • Join NEC
  • Issues
    • Diversity & Inclusion
    • Energy & Environment
    • Financial Services
    • Healthcare
    • Higher Education
    • Housing
    • Technology & Innovation
    • Trade
    • Transportation & Infrastructure
    • Partnerships for Talent Pipeline Directory
  • Programs
    • Rising Stars Network
    • New England Council Fellows Program
    • Inside the Corner Office
    • Celebrating 100 Years
  • News
  • Events
    • Upcoming Events
    • Past Events
    • 2025 Centennial Celebration
    • Washington Leaders’ Conference
    • Politics & Eggs
    • Sponsorship Opportunities
  • Contact
  • About
    • Staff
    • Board of Directors
    • Member Directory
  • Membership
    • Membership Benefits
    • Membership FAQ
    • Join NEC
  • Issues
    • Diversity & Inclusion
    • Energy & Environment
    • Financial Services
    • Healthcare
    • Higher Education
    • Housing
    • Technology & Innovation
    • Trade
    • Transportation & Infrastructure
    • Partnerships for Talent Pipeline Directory
  • Programs
    • Rising Stars Network
    • New England Council Fellows Program
    • Inside the Corner Office
    • Celebrating 100 Years
  • News
  • Events
    • Upcoming Events
    • Past Events
    • 2025 Centennial Celebration
    • Washington Leaders’ Conference
    • Politics & Eggs
    • Sponsorship Opportunities
  • Contact

News

Sep 15, 2022Blog | Member News, Healthcare

Boston Scientific updates post-procedural care options for atrial appendage closure device

New England Council member Boston Scientific Corporation received FDA approval to expand instructions on the WATCHMAN FLX Left Atrial Appendage Closure device which now provides doctors with another tool to prevent blood clots after the device is inserted.

With this new expansion, doctors now have an alternative treatment option for patients with non-valvular atrial fibrillation. Now, doctors can use the device along with a 45-day dual antiplatelet therapy as opposed to a 45-day oral anticoagulation and aspirin post-procedural treatment. In Europe, this labeling to include both post-procedural drugs have been in place since 2017. This new expansion will give doctors more freedom to determine the best treatment option for each individual patient.

Dr. Ian Meredith, global chief medical officer at Boston Scientific, said, “this revised labeling provides physicians more flexibility to exercise their clinical judgment based on individual patient characteristics to determine the most appropriate post-procedural antithrombotic medication regimen.”
The New England Council work like to congratulate Boston Scientific on its commitment to developing life-changing technologies.

Read more from Boston Scientific and Worcester Business Journal.

Council Related News
Read Article Blog | Member News, Higher Education

University of New England joins global entrepreneurship network

Read Article Blog | Member News, Higher Education

Framingham State University museum receives largest donation in 50-year history

Read Article Blog | Member News, Healthcare

Point32Health hires new CEO

Read Article Blog | Member News, Healthcare

Dana-Farber plans to hire 700 new nurses

Read Article Blog | Member News, Transportation & Infrastructure

Massachusetts Port Authority is pushing to make MA a hub for sustainable aviation fuels

View Related News

©2025 New England Council
All rights reserved.

Privacy Policy Website Design by Jackrabbit

Boston Office

98 North Washington Street
Suite 303
Boston, MA 02114

(617) 723-4009

necouncil@newenglandcouncil.com

Washington Office

1411 K Street, NW
Suite 700
Washington, D.C. 20005

(202) 547-0048

necouncil@newenglandcouncil.com

Website Design by Jackrabbit